CN103298784A - 一种酪氨酸激酶抑制剂的盐形式 - Google Patents

一种酪氨酸激酶抑制剂的盐形式 Download PDF

Info

Publication number
CN103298784A
CN103298784A CN2012800049182A CN201280004918A CN103298784A CN 103298784 A CN103298784 A CN 103298784A CN 2012800049182 A CN2012800049182 A CN 2012800049182A CN 201280004918 A CN201280004918 A CN 201280004918A CN 103298784 A CN103298784 A CN 103298784A
Authority
CN
China
Prior art keywords
indoles
methyl
fluoro
diethylin
subunits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012800049182A
Other languages
English (en)
Other versions
CN103298784B (zh
Inventor
唐锋
金秋
李薇
朱甜
胡扬
邵凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Yoko Biomedical R & D Ltd
NANJING YOKO PHARMACEUTICAL CO Ltd
Original Assignee
Jiangsu Simcere Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical R&D Co Ltd filed Critical Jiangsu Simcere Pharmaceutical R&D Co Ltd
Priority to CN201280004918.2A priority Critical patent/CN103298784B/zh
Publication of CN103298784A publication Critical patent/CN103298784A/zh
Application granted granted Critical
Publication of CN103298784B publication Critical patent/CN103298784B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

本发明涉及(Z)-N-[2-(二乙胺基)乙基]-2-甲基-7-(1,2-二氢-5-氟-2-氧代-3H-吲哚-3-亚基)-4,5,6,7-四氢-1H-吲哚-3-羧酰胺的酸加成盐，其选自L-苹果酸盐、盐酸盐、磷酸盐、L-酒石酸盐、苯磺酸盐、硫酸盐、甲烷磺酸盐、丁二酸盐、柠檬酸盐、富马酸盐、对甲苯磺酸盐、氢溴酸盐、L-扁桃酸盐、乳酸盐、乙酸盐和马来酸盐；以及上述盐化合物在制备药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280004918.2A 2011-03-15 2012-03-12 一种酪氨酸激酶抑制剂的盐形式 Expired - Fee Related CN103298784B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280004918.2A CN103298784B (zh) 2011-03-15 2012-03-12 一种酪氨酸激酶抑制剂的盐形式

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2011100617741A CN102675184A (zh) 2011-03-15 2011-03-15 一种酪氨酸激酶抑制剂的盐形式
CN2011100617741 2011-03-15
CN201110061774.1 2011-03-15
PCT/CN2012/072174 WO2012122921A1 (zh) 2011-03-15 2012-03-12 一种酪氨酸激酶抑制剂的盐形式
CN201280004918.2A CN103298784B (zh) 2011-03-15 2012-03-12 一种酪氨酸激酶抑制剂的盐形式

Publications (2)

Publication Number Publication Date
CN103298784A true CN103298784A (zh) 2013-09-11
CN103298784B CN103298784B (zh) 2015-07-15

Family

ID=46807806

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011100617741A Pending CN102675184A (zh) 2011-03-15 2011-03-15 一种酪氨酸激酶抑制剂的盐形式
CN201280004918.2A Expired - Fee Related CN103298784B (zh) 2011-03-15 2012-03-12 一种酪氨酸激酶抑制剂的盐形式

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011100617741A Pending CN102675184A (zh) 2011-03-15 2011-03-15 一种酪氨酸激酶抑制剂的盐形式

Country Status (3)

Country Link
US (1) US9018242B2 (zh)
CN (2) CN102675184A (zh)
WO (1) WO2012122921A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664738A (zh) * 2012-09-12 2014-03-26 南京优科生物医药研究有限公司 一种羧酰胺化合物l-苹果酸盐的结晶多晶型物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103833766B (zh) * 2012-11-23 2016-12-21 天津尚德药缘科技股份有限公司 阿格拉滨二甲胺富马酸盐及其在药物制备中的用途
WO2023186137A1 (zh) * 2022-04-01 2023-10-05 成都百裕制药股份有限公司 吲哚酮衍生物及其在医药上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195601A (zh) * 2006-12-04 2008-06-11 江苏先声药物研究有限公司 2-二氢吲哚酮衍生物及其制备方法和用途
CN101200446A (zh) * 2006-12-15 2008-06-18 江苏先声药物研究有限公司 3-吡咯并环己亚基-2-二氢吲哚酮衍生物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123649B1 (en) * 2006-12-04 2012-02-29 Jiangsu Simcere Pharmaceutical R&D Co., Ltd. 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195601A (zh) * 2006-12-04 2008-06-11 江苏先声药物研究有限公司 2-二氢吲哚酮衍生物及其制备方法和用途
CN101200446A (zh) * 2006-12-15 2008-06-18 江苏先声药物研究有限公司 3-吡咯并环己亚基-2-二氢吲哚酮衍生物及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664738A (zh) * 2012-09-12 2014-03-26 南京优科生物医药研究有限公司 一种羧酰胺化合物l-苹果酸盐的结晶多晶型物

Also Published As

Publication number Publication date
WO2012122921A1 (zh) 2012-09-20
CN103298784B (zh) 2015-07-15
US9018242B2 (en) 2015-04-28
US20140011856A1 (en) 2014-01-09
CN102675184A (zh) 2012-09-19

Similar Documents

Publication Publication Date Title
US10596174B2 (en) Pyrrolopyrimidine compounds as inhibitors of protein kinases
US11007197B2 (en) EGFR modulators and uses thereof
DK2880035T3 (en) Hitherto UNKNOWN PYRROLOPYRIMIDINE COMPOUNDS AS PROTEIN CHINAS INHIBITORS
US10793543B2 (en) Selective C-KIT kinase inhibitor
AU2018275277B2 (en) Pharmaceutically acceptable salt of EGFR inhibitor, crystal form thereof, preparation method therefor and application thereof
US10710996B2 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
CN104829610B (zh) 一种新型布鲁顿酪氨酸激酶抑制剂
BR112021008516A2 (pt) Inibidores de quinase 7 dependente de ciclina (cdk 7)
US9586965B2 (en) Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
CN102086195A (zh) 达沙替尼多晶型物及其制备方法和药用组合物
ES2872775T3 (es) Compuestos de pirropirimidina como inhibidores de MNK
CN104470920A (zh) 固态形式的维罗菲尼胆碱盐
CN107540661A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN113773305B (zh) 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用
CN103298784A (zh) 一种酪氨酸激酶抑制剂的盐形式
RU2761825C1 (ru) Соединения дейтерированного дефактиниба и их применение
CN109516991A (zh) 一种枸橼酸托法替尼晶型化合物及其制备方法
CN113260613B (zh) 一种egfr抑制剂的盐、晶型及其制备方法
CN103159741A (zh) 一类新型的酪氨酸激酶抑制剂的制备和用途
CN103172578A (zh) 4-环末端取代2-1,2,3-三氮唑苯胺类化合物的制备和用途
WO2023006057A1 (zh) 氨基吡唑并嘧啶化合物的晶体
CN103664738B (zh) 一种羧酰胺化合物l-苹果酸盐的结晶多晶型物
CN108026078A (zh) 1-(4-(2-((1-(3,4-二氟苯基)-1h-吡唑-3-基)甲氧基)乙基)哌嗪-1-基)乙酮盐
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
CN114957136A (zh) 一种用作vegfr抑制剂的抗肿瘤化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: NANJING YOKO BIOLOGICAL PHARMACEUTICAL RESEARCH CO

Free format text: FORMER OWNER: JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LIMITED

Effective date: 20131106

Owner name: NANJING YOKO PHARMACEUTICAL CO., LTD.

Effective date: 20131106

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 210042 NANJING, JIANGSU PROVINCE TO: 210046 NANJING, JIANGSU PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20131106

Address after: 210046, No. 28, Heng Jing Road, Nanjing economic and Technological Development Zone, Jiangsu, Nanjing

Applicant after: NANJING YOKO BIOMEDICAL R & D Ltd.

Applicant after: NANJING YOKO PHARMACEUTICAL Co.,Ltd.

Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18

Applicant before: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150715